Witt Russell G, Newhook Timothy E, Prakash Laura R, Bruno Morgan L, Arvide Elsa M, Dewhurst Whitney L, Ikoma Naruhiko, Maxwell Jessica E, Kim Michael P, Lee Jeffrey E, Katz Matthew H G, Tzeng Ching-Wei D
Department of Surgical Oncology, University of Texas, M. D. Anderson Cancer Center, Houston, Texas.
Department of Surgical Oncology, University of Texas, M. D. Anderson Cancer Center, Houston, Texas.
J Surg Res. 2022 Jul;275:244-251. doi: 10.1016/j.jss.2022.02.031. Epub 2022 Mar 17.
The initial settings on an intravenous patient-controlled analgesia (IV-PCA) pump can represent a significant source of postoperative opioid exposure. The primary aim of this study was to evaluate the impact of first day IV-PCA use on total inpatient opioid use after open pancreatectomy, before and after standardization of initial dosing.
Inpatient oral morphine equivalents (OMEs) were reviewed for pancreatectomy patients treated with IV-PCA at a single institution before and after (3/2016-8/2017 versus 3/2019-11/2020) implementation of a standardized initial IV-PCA dosing regimen (initial limit 0.1 mg hydromorphone, or 1 mg OME, every 10 min as needed). IV-PCA OME in the first 24 h and the total inpatient OME were compared between cohorts.
Of 220 total patients, 132 were in the prestandardization (PRE) historical cohort. A first-24-h IV-PCA use was different (PRE median 95 mg versus poststandardization [POST] 15 mg, P < 0.001). The median total inpatient OME was different (P < 0.001) between PRE (525 mg, interquartile range [IQR] 239-951 mg) and POST patients (129 mg, IQR 65-204 mg) with 77% (median 373 mg) of total inpatient OMEs contributed by IV-PCA in the PRE and 56% (median 64 mg) in the POST cohorts. There were similar patient-reported pain scores between groups.
Standardizing initial IV-PCA settings was associated with a reduced first-24-h opioid exposure, proportional and absolute total IV-PCA use, and total inpatient OMEs. Because of the contribution of an IV-PCA to the total inpatient opioid exposure, purposeful reduction or omission of an IV-PCA is critical to perioperative opioid reduction strategies.
静脉自控镇痛(IV-PCA)泵的初始设置可能是术后阿片类药物暴露的一个重要来源。本研究的主要目的是评估在初始剂量标准化前后,开腹胰腺切除术后首日使用IV-PCA对住院期间阿片类药物总使用量的影响。
回顾了在单一机构接受IV-PCA治疗的胰腺切除术患者在实施标准化初始IV-PCA给药方案(初始限制为每10分钟按需给予0.1毫克氢吗啡酮或1毫克口服吗啡当量[OME])前后(2016年3月至2017年8月与2019年3月至2020年11月)的住院口服吗啡当量(OME)。比较了各队列中前24小时的IV-PCA OME和住院期间的总OME。
在220例患者中,132例属于标准化前(PRE)的历史队列。前24小时IV-PCA的使用情况有所不同(PRE中位数为95毫克,标准化后[POST]为15毫克,P<0.001)。PRE组(525毫克,四分位数间距[IQR]为239-951毫克)和POST组患者(129毫克,IQR为65-204毫克)的住院期间总OME中位数不同(P<0.001),PRE组中77%(中位数为373毫克)的住院期间总OME由IV-PCA贡献,POST组为56%(中位数为64毫克)。两组患者报告的疼痛评分相似。
标准化初始IV-PCA设置与减少前24小时阿片类药物暴露、成比例和绝对的IV-PCA总使用量以及住院期间总OME相关。由于IV-PCA对住院期间阿片类药物总暴露的贡献,有目的地减少或不使用IV-PCA对于围手术期阿片类药物减少策略至关重要。